Athenahealth (ATHN) Tops Q2 EPS by 12c, Affirms Outlook
Get Alerts ATHN Hot Sheet
Price: $9.59 --0%
Financial Fact:
Research and development: 24.86M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Research and development: 24.86M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Athenahealth (NASDAQ: ATHN) reported Q2 EPS of $0.51, $0.12 better than the analyst estimate of $0.39. Revenue for the quarter came in at $301.1 million versus the consensus estimate of $298.68 million.
Fiscal Year 2017 Outlook
We are reaffirming our fiscal year 2017 financial guidance we communicated on April 27, 2017 with the release of our first quarter fiscal year results. Our fiscal year 2017 financial guidance is summarized in the following table:
| For the Fiscal Year Ending December 31, 2017 | |
| Forward-Looking Guidance | |
| Financial Measures | |
| GAAP Total Revenue | $1,210 million - $1,250 million |
| GAAP Operating Income | $36 million - $46 million |
| Non-GAAP Adjusted Operating Income | $120 million - $140 million |
| Financial Metric | |
| Annual Bookings | $350 million - $400 million |
For earnings history and earnings-related data on Athenahealth (ATHN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share